134 related articles for article (PubMed ID: 17570704)
1. Reducing irinotecan-associated diarrhea in children.
Wagner LM; Crews KR; Stewart CF; Rodriguez-Galindo C; McNall-Knapp RY; Albritton K; Pappo AS; Furman WL
Pediatr Blood Cancer; 2008 Feb; 50(2):201-7. PubMed ID: 17570704
[TBL] [Abstract][Full Text] [Related]
2. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Schmittel A; Jahnke K; Thiel E; Keilholz U
Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
[No Abstract] [Full Text] [Related]
3. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN
Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062
[No Abstract] [Full Text] [Related]
4. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).
Med Lett Drugs Ther; 2006 May; 48(1234):39-40. PubMed ID: 16685247
[No Abstract] [Full Text] [Related]
5. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
[TBL] [Abstract][Full Text] [Related]
7. How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?
Nariai H; Shitara T; Oto Y; Natsumeda T; Taniuchi M; Sato Y
Pediatr Blood Cancer; 2009 Jan; 52(1):145. PubMed ID: 18798559
[No Abstract] [Full Text] [Related]
8. Irinotecan toxicity.
Anthony L
Curr Opin Support Palliat Care; 2007 Apr; 1(1):35-9. PubMed ID: 18660722
[TBL] [Abstract][Full Text] [Related]
9. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1171-7. PubMed ID: 12145998
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide and irinotecan-associated diarrhea.
Tchekmedyian NS
Am J Clin Oncol; 2002 Jun; 25(3):324. PubMed ID: 12040298
[No Abstract] [Full Text] [Related]
11. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between UGT1A and irinotecan-related toxicity].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
[No Abstract] [Full Text] [Related]
13. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
Tamura T; Yasutake K; Nishisaki H; Nakashima T; Horita K; Hirohata S; Ishii A; Hamano K; Aoyama N; Shirasaka D; Kamigaki T; Kasuga M
Oncology; 2004; 67(5-6):327-37. PubMed ID: 15713987
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Swami U; Goel S; Mani S
Curr Drug Targets; 2013 Jun; 14(7):777-97. PubMed ID: 23597015
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Cosetti M; Wexler LH; Calleja E; Trippett T; LaQuaglia M; Huvos AG; Gerald W; Healey JH; Meyers PA; Gorlick R
J Pediatr Hematol Oncol; 2002 Feb; 24(2):101-5. PubMed ID: 11990694
[TBL] [Abstract][Full Text] [Related]
16. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal toxicity or irinotecan.
Hecht JR
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):72-8. PubMed ID: 9726096
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
Nikolic-Tomasevic Z; Jelic S; Popov I; Radosavljevic D
J Chemother; 2000 Jun; 12(3):244-51. PubMed ID: 10877521
[TBL] [Abstract][Full Text] [Related]
20. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Mori K; Kondo T; Kamiyama Y; Kano Y; Tominaga K
Cancer Chemother Pharmacol; 2003 May; 51(5):403-6. PubMed ID: 12687289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
